Why Is CAPRICOR THERAPEUTIC (CAPR) Stock Moving Today?
By the Top Tier Newswire AI Desk · August 17, 2026 at 12:20 AM ET · reviewed against 8 wire stories
CAPRICOR THERAPEUTIC (CAPR) is drawing unusual attention today. Our newswire has captured 8 stories on CAPR across 4 sources in the last 36 hours, with AI sentiment reading mixed (avg 48/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
Why CAPR stock is moving today
CAPR stock is moving higher today, having risen by 65.9% over the last eight sessions, as a mix of legal developments and a recent upgrade from Cantor Fitzgerald has drawn investor attention. The stock has traded between $2.96 and $40.37 in the past 52 weeks and is currently valued at a market cap of $242.1 million. The recent upgrade to Overweight from Neutral at Cantor Fitzgerald, combined with a flurry of investor alerts regarding ongoing class action lawsuits, has contributed to the recent upward momentum.
What Happened
Capricor Therapeutics is currently facing multiple class action lawsuits, with lead plaintiff deadlines set for September 28 and September 29, 2026. Legal firms including Kessler Topaz Meltzer & Check, LLP, Robbins Geller Rudman Dowd LLP, and Faruqi & Faruqi, LLP have encouraged investors with alleged losses to participate. These developments have heightened scrutiny on the company’s operations and financial disclosures. Meanwhile, Cantor Fitzgerald upgraded the stock to Overweight from Neutral, citing a “major update” from the company’s earnings call. Capricor reported Q2 earnings per share of -$0.70, below the consensus estimate of -$0.58, and the company expects its cash reserves to fund operations for at least 12 months.
What The Data Shows
Over the last 30 days, sentiment has improved from an average of 44 to 49 out of 100. The stock has seen unusual price movement, rising from $3.93 to $6.52 in the past eight sessions. Insider selling has been notable, with four sales totaling $1.5 million reported in the last 90 days. The stock has also shown a relatively low beta of 0.53, indicating it is less volatile than the broader market. However, the company remains unprofitable, with a trailing twelve-month earnings per share of -$2.32 and a year-over-year revenue decline of 52.1%.
What To Watch
The next key event for Capricor Therapeutics is the lead plaintiff deadline for the ongoing class action lawsuits, which investors should monitor for any potential regulatory or legal developments.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
CAPR · Aug 17 session (5-min) · +12.61% vs prior close · updated 8:57 PM ETAI sentiment, last 36h · averaged over 8 stories · 48/100 neutral
The headlines behind the move
Story flow · 8 stories on the wire, last 36h · hover or tap a dot for the headline
27d agoBarchartNEUTRAL 50General
CAPR Investor Alert: Kessler Topaz Meltzer & Check, LLP Encourages CAPR Investors with Losses to Contact the Firm
Comprehensive up-to-date news coverage, aggregated from sources all over the world by Google News.
27d agoBusiness InsiderBEARISH 34General
CAPR INVESTOR ALERT: Capricor Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit before September 28, 2026 Deadline
San Diego, California--(Newsfile Corp. - August 16, 2026) - Robbins Geller Rudman Dowd LLP ...
27d agoBusiness InsiderNEUTRAL 50General
CAPR UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds Capricor Investors of Securities Class Action Lawsuit Deadline on September 29, 2026
Faruqi Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages...
27d agoGlobeNewswireBEARISH 34General
Bronstein, Gewirtz & Grossman LLC Urges Capricor Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
New class action for Capricor (CAPR) urges investors to seek recovery for alleged securities fraud violations – lead plaintiff deadline of 9/28/2026...
27d agoThe FlyNEUTRAL 52General
Capricor Therapeutics expects cash to fund operations for at least 12 months
Capricor Therapeutics upgraded to Overweight from Neutral at Cantor Fitzgerald
27d agoThe FlyBULLISH 63Analyst
Cantor upgrades Capricor on ‘major update’ from earnings call
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →